In vitro activities of two new glycylcyclines, N,N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria.
The in vitro activities of the N,N-dimethylglycylamido derivatives of minocycline (DMG-MINO) and 6-demethyl-6-deoxytetracycline (DMG-DMDOT) were compared with those of minocycline, tetracycline, clindamycin, and metronidazole by using the National Committee for Clinical Laboratory Standards-approved Wadsworth agar dilution method. The MICs of DMG-MINO, DMG-DMDOT, and metronidazole at which 90% of the strains were susceptible (0.5, 1, and 1 micrograms/ml, respectively) were lower than those for clindamycin, minocycline, and tetracycline (4, 8, and 32 micrograms/ml, respectively). All of the strains of anaerobes tested, except one strain of Bacteroides ovatus (MIC, 16 micrograms/ml), were susceptible to DMG-MINO and DMG-DMDOT at 8 micrograms/ml.
Wexler
H M
HM
Medical Service, Veterans Administration Medical Center, West Los Angeles, California 90073.
Molitoris
E
E
Finegold
S M
SM
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D002981:Clindamycin / Q000494:pharmacology; D008795:Metronidazole / Q000494:pharmacology; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013754:Tetracyclines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D013754:Tetracyclines; D008795:Metronidazole; C085305:9-(N,N-dimethylglycylamido)minocycline; C085306:6-demethyl-9-(N,N-dimethylglycylamido)-6-deoxytetracycline; D002981:Clindamycin; D008911:Minocycline